Citadel Advisors
DBTX

Citadel Advisors’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Citadel Advisors’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-76,100
Closed -$156K – 15883
2022
Q4 		$156K Sell
76,100
-12,500
-14% -$38.1K ﹤0.01% 10555
2022
Q3 		$307K Sell
88,600
-101,100
-53% -$460K ﹤0.01% 9529
2022
Q2 		$799K Buy
189,700
+127,500
+205% +$301K ﹤0.01% 7548
2022
Q1 		$189K Buy
62,200
+8,800
+16% +$33.7K ﹤0.01% 11608
2021
Q4 		$248K Buy
+53,400
New +$368K ﹤0.01% 11393

Other funds holding DBTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's DBTX Position: Q1 2023 in Review

Citadel Advisors sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q1 2023, closing a stake of 1,787,311 shares — an estimated $3.66M sold.

Citadel Advisors first reported a position in DBTX in Q1 2021 and held it in 8 quarters. The position peaked at $20.2M in Q1 2021. 38 funds tracked by Wall St. Rank hold DBTX as of Q1 2023.

  • Citadel Advisors reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,787,311 Decibel Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.66M.
  • Citadel Advisors first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Citadel Advisors's Decibel Therapeutics, Inc. Common Stock position peaked at $20.2M in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.